Antiphospholipid Syndrome
Introduction
Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a chronic autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) in the blood. These antibodies target phospholipid-binding proteins, leading to an increased risk of blood clots (thrombosis) in both arteries and veins, as well as complications during pregnancy, such as recurrent miscarriages, pre-eclampsia, and premature birth.
Biological Basis
The biological basis of APS involves an aberrant immune response where the body produces autoantibodies against its own proteins that bind to phospholipids. Key antibodies associated with APS include lupus anticoagulant (LA), anti-cardiolipin antibodies (aCL), and anti-beta-2-glycoprotein I antibodies (anti-β2GPI). These antibodies interfere with the normal coagulation process, promoting a hypercoagulable state. While the exact mechanisms are complex and still being researched, it is understood that these antibodies can activate endothelial cells, platelets, and complement pathways, contributing to thrombus formation. Genetic factors are thought to play a role in susceptibility to APS, though it is not a monogenic disorder.
Clinical Relevance
Clinically, APS presents with a wide range of manifestations, most commonly including venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism), arterial thrombosis (e.g., stroke, transient ischemic attack, myocardial infarction), and obstetric complications. Other manifestations can include thrombocytopenia (low platelet count), livedo reticularis (a lace-like skin discoloration), and neurological symptoms. Diagnosis typically involves a combination of clinical criteria (history of thrombosis or pregnancy morbidity) and laboratory findings (persistent presence of antiphospholipid antibodies). Management often involves lifelong anticoagulation therapy to prevent recurrent thrombotic events.
Social Importance
The social importance of antiphospholipid syndrome is significant due to its potential for severe and life-threatening complications. It can affect individuals of any age, though it is more common in women, particularly those of childbearing age. The risk of recurrent thrombosis necessitates ongoing medical care and often impacts daily life, work, and family planning. For pregnant individuals, APS poses a substantial risk to both maternal and fetal health, requiring specialized care to achieve successful pregnancy outcomes. Increased awareness and early diagnosis are crucial for effective management, preventing disability, and improving the quality of life for those affected by this complex autoimmune condition.
Methodological and Statistical Constraints
Initial genome-wide association studies (GWAS) for antiphospholipid antibodies (APA) were conducted on relatively modest sample sizes, such as cohorts ranging from 496 to 708 individuals for specific APA types. [1] This limitation significantly impacts statistical power, leading to a reduced ability to detect genetic variants with small to moderate effect sizes. [2] Consequently, while several suggestive loci were identified with P-values less than 1E-05, none met the stringent threshold for genome-wide significance (P < 5E-08), indicating that the observed associations are preliminary and require further validation. [1]
The suggestive nature of these initial findings underscores the critical need for independent replication in larger cohorts to confirm genetic associations and reduce the risk of false positives, a common challenge in GWAS. [1] Without robust replication, particularly of variants showing marginal significance in discovery phases, it is difficult to distinguish true genetic signals from chance findings. [3] The observed lack of overlap among top loci for different APA types in some analyses further highlights the complexity and the potential for spurious associations when sample sizes are insufficient. [1]
Phenotypic Heterogeneity and Measurement Challenges
The definition of antiphospholipid syndrome (APS) and the underlying antiphospholipid antibodies (APA) is inherently complex, involving multiple distinct antibody specificities, such as anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), and anti-𝛽2 glycoprotein I antibodies (anti-𝛽2GPI). [1] This heterogeneity means that different APA types may have distinct genetic determinants, complicating efforts to identify overarching susceptibility loci. [1] Studies that analyze single antibody types may also inadvertently include individuals positive for other APA in either the case or control groups, potentially confounding genetic association outcomes and obscuring true genetic signals. [1]
The measurement and classification of APA status are based on manufacturer's protocols, which can introduce variability and may not fully capture the clinical spectrum or biological mechanisms of APS. [1] The presence of these antibodies can also be influenced by other autoimmune conditions, such as systemic lupus erythematosus (SLE), which necessitates careful adjustment in statistical analyses to isolate genetic effects specific to APA. [1] However, despite adjustments for known confounders like SLE, smoking, and body mass index, the intricate interplay of various factors in defining APA positivity remains a challenge in genetic studies. [1]
Generalizability and Unaccounted Confounders
The generalizability of identified genetic associations is limited by the ancestry of the study populations, with some studies focusing on cohorts of specific descents, such as German. [4] Genetic findings from one population may not directly translate to others due to differences in allele frequencies, linkage disequilibrium patterns, or varying environmental exposures across diverse ancestral groups. [2] While efforts are made to control for population stratification through methods like principal component analysis, residual ancestral differences could still contribute to spurious associations or mask genuine ones. [1]
Beyond measured covariates like smoking and body mass index, a myriad of unmeasured environmental factors and their complex interactions with genetic predispositions likely contribute to APA development and APS. [1] These gene-environment interactions, along with potential epigenetic modifications, represent significant knowledge gaps that current GWAS methodologies, primarily focused on common genetic variants, may not fully capture. The "missing heritability" for complex traits like APA suggests that a substantial portion of genetic influence may still be undiscovered, possibly residing in rare variants, structural variations, or complex epistatic interactions not adequately addressed by current study designs. [5]
Definition and Core Characteristics
Antiphospholipid syndrome (APS) is precisely defined as a condition characterized by venous and/or arterial thrombosis and pregnancy morbidity in women, coupled with the persistent presence of antiphospholipid antibodies (aPL). [4] The persistent detection of these antibodies, also referred to as APA, is an essential component for the development and diagnosis of the syndrome. [1] This definition establishes APS as an autoimmune disorder where the immune system produces antibodies that predispose individuals to blood clot formation and adverse pregnancy outcomes.
Classification and Diagnostic Framework
APS is classified into primary and secondary forms, based on the presence or absence of an underlying autoimmune disease. [1] Individuals are categorized as having secondary APS when an associated autoimmune condition is identified. [1] The diagnosis of APS relies on established criteria that combine clinical events with specific laboratory findings, requiring the measurement of more than one antiphospholipid antibody. [1]
Key Terminology and Diagnostic Markers
The central terminology revolves around specific antiphospholipid antibodies, which serve as critical biomarkers for APS. [4] These include anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), and anti-β2GPI antibodies (anti-β2GPI). [1] Measurement approaches involve determining titers of IgG and IgM against cardiolipin, anti-β2GPI, and IgG against domain 1 of β2GPI. [4] For diagnostic purposes, these antibodies are categorized as positive or negative based on manufacturer’s protocols [1] with recognized laboratory criteria requiring the presence of one or more of these three types of antibodies in conjunction with clinical manifestations. [1]
Vascular and Reproductive Manifestations
Antiphospholipid syndrome (APS) is primarily characterized by significant vascular and reproductive clinical presentations. A hallmark feature involves the occurrence of both venous and/or arterial thrombosis, which can affect various organ systems and present with a wide range of severities. [4] In women, a critical presentation pattern is pregnancy morbidity, encompassing adverse outcomes such as recurrent miscarriage, pre-eclampsia, or stillbirth. [4] These thrombotic events or pregnancy complications serve as key clinical indicators, prompting further diagnostic investigation for underlying APS.
Antiphospholipid Antibody Profiles and Diagnostic Assessment
The diagnosis of antiphospholipid syndrome is intrinsically linked to the persistent presence of specific antiphospholipid antibodies (aPL), also referred to as antiphospholipid antibodies (APA). [4] Key measurement approaches involve determining titres of IgG and IgM against cardiolipin (ACL), IgG and IgM against β2glycoprotein 1 (anti-β2GPI), and IgG against domain 1 of β2GPI . This presents as a specific clinical phenotype, where kidney disease can manifest in varying degrees of severity and contribute to the overall burden of the syndrome. [6] The assessment of renal function and specific kidney-related symptoms becomes crucial in patients suspected of or diagnosed with APS, as it informs the comprehensive clinical picture and guides management.
There is considerable phenotypic diversity and inter-individual variation in how renal involvement presents in APS. Notably, research indicates that IgM anti-β2glycoprotein I antibodies may be protective against the development of lupus nephritis and general renal damage in patients with systemic lupus erythematosus. [7] This highlights the complex and sometimes nuanced diagnostic significance of specific antibody subtypes, where certain antibody profiles can act as prognostic indicators or suggest differential disease courses. Age and BMI are also considered in association analyses with APA status, suggesting potential influences on disease variability. [1]
Molecular Mechanisms of Coagulation and Thrombosis
Antiphospholipid syndrome (APS) is characterized by a propensity for blood clot formation, a process intricately regulated by the coagulation cascade. A central component of this regulation is the protein C anticoagulant pathway, involving key biomolecules such as Protein C (PC), free Protein S (fPS), functional Protein S (funcPS), and total Protein S (total PS). [8] The endothelial cell-specific transmembrane protein, Endothelial Protein C Receptor (EPCR), encoded by the PROCR gene, plays a crucial role in this pathway by enhancing the activation rate of PC. Disruptions in this pathway are significant, as increased levels of soluble EPCR (sEPCR) have been directly linked to an elevated risk of thrombotic events. [8]
Genetic variations within the PROCR gene can profoundly influence these processes. For instance, the single nucleotide polymorphism rs867186, located in exon 4 of PROCR, results in an amino acid change (S219G) that is associated with altered PC plasma levels and an increased risk of venous thrombosis. [8] Beyond the protein C pathway, other coagulation factors also contribute to thrombotic risk. A variant in the 5' untranslated region of F12, the gene encoding clotting factor XII, acts as a protein quantitative trait locus (pQTL) for thrombin and plasma serine protease inhibitor, thereby influencing thrombin generation and the overall coagulation cascade. [9] Furthermore, the gene PRR12 has been associated with fibrinogen concentrations, a critical protein involved in clot formation and a recognized high-risk marker for vascular inflammatory diseases and cardiovascular complications. [10]
Immune System Dysregulation and Cellular Signaling
The immune system plays a significant role in the pathophysiology of various autoimmune conditions, including those that share genetic and mechanistic overlap with APS. Lipid metabolism, particularly the levels of high-density lipoprotein (HDL), is often altered in autoimmune diseases, with reduced HDL observed in conditions such as systemic lupus erythematosus and rheumatoid arthritis. [11] The PLTP gene, encoding phospholipid transfer protein, is instrumental in regulating HDL metabolism; its reduced expression can lead to decreased fusion of small HDL molecules, which in turn may impair the regulation of T- and B-cell activity, key components of the adaptive immune response. [11]
Complement system dysregulation is another critical aspect, highlighted by the CFH locus where a protective allele leading to a common deletion of CFHR1 and CFHR3 is associated with reduced expression of these complement factors in tissues like the liver and kidney. [12] This genetic variation results in a widespread proteomic and metabolomic signature in blood, impacting the regulation of the complement cascade. [12] Cellular signaling pathways involving phospholipases are also implicated; PLCL1 is involved in inositol phospholipid-based intracellular signaling and receptor turnover, while PLCL2 contributes to B-cell receptor signaling . [13], [14] The immune synapse, crucial for T-cell activation, is regulated by proteins like LIMK1, which controls actin-dependent processes, and ARL14, a GTPase involved in MHC class II vesicle recruitment and dendritic cell movement, with specific genetic variants influencing their promoters and expression in dendritic cells. [10] The PF4V1 locus further supports immune involvement, showing enrichment in the 'positive regulation of neutrophil chemotaxis'. [12]
Genetic Architecture and Regulatory Networks
Genetic mechanisms underpin the predisposition and progression of complex diseases like APS, with variations influencing gene and protein expression. Genome-wide association studies (GWAS) have identified numerous loci where single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) or protein quantitative trait loci (pQTLs), modulating the abundance of specific transcripts or proteins . [11], [12], [15] These genetic variants can have profound functional implications, for example, the rs867186 SNP in the PROCR gene, which causes an S219G amino acid change, directly influences plasma levels of Protein C and affects thrombotic risk. [8] Similarly, a variant in the 5' untranslated region of F12 functions as a pQTL for thrombin and plasma serine protease inhibitor, thereby modulating the coagulation cascade. [9]
The impact of genetic variations can extend beyond direct coding changes. Differential eQTL effects have been observed, such as varying PLTP expression patterns in celiac disease versus rheumatoid arthritis, leading to distinct metabolic and immune consequences. [11] Genetic loci can exhibit pleiotropic effects, affecting the levels of multiple proteins in both cis (nearby genes) and trans (distant genes), as exemplified by the CFH locus which influences numerous proteins, including those involved in complement regulation . [12], [15] Furthermore, non-coding disease variants can interact physically with gene promoters, such as rs193107685 with the LIMK1 promoter and rs112846137 with the ARL14 promoter in dendritic cells, suggesting complex regulatory networks that shape immune responses. [10] The lineage-specific genome architecture also plays a role in linking enhancers and non-coding disease variants to target gene promoters, providing a framework for understanding how genetic variations contribute to disease. [16]
Systemic Manifestations and Tissue-Specific Effects
The biological disruptions in APS extend to systemic consequences affecting multiple tissues and organs, often leading to widespread clinical manifestations. The dysregulation of coagulation and immune pathways contributes significantly to an increased risk of thrombotic events and cardiovascular disease. [10] Key biomolecules like fibrinogen, whose concentrations are influenced by genes such as PRR12, serve as crucial indicators for vascular inflammatory diseases and are predictive of cardiovascular complications. [10] Metabolic disturbances are also evident, with varying levels of HDL observed across autoimmune diseases; for instance, reduced HDL levels in systemic lupus erythematosus and rheumatoid arthritis may contribute to heightened cardiovascular risk. [11]
Certain genetic loci demonstrate broad systemic impacts due to their pleiotropic effects. The APOE locus, for example, is well-known for its associations with hypercholesterolemia, atherosclerotic heart disease, and Alzheimer's disease, and has been shown to affect the levels of multiple proteins, including matrix metalloproteinases and immune-related proteins. [9] At the tissue level, specific genetic variants can lead to localized effects that have systemic repercussions. A protective allele at the CFH locus, for instance, results in reduced expression of CFHR1 and CFHR3 in the liver, kidney, and other tissues, thereby impacting the complement system and contributing to broader immune dysregulation. [12] The presence of citrullination within atherosclerotic plaques, a potential target for autoantibody responses in rheumatoid arthritis, further illustrates the intricate interplay between inflammation, immune responses, and vascular pathology that can have systemic implications. [17]
Antibody-Mediated Cellular Dysregulation
The persistent presence of antiphospholipid antibodies (aPL), including anticardiolipin antibodies (ACL) and anti-β2 glycoprotein I (anti-β2GPI), is a central pathogenic factor in antiphospholipid syndrome (APS), driving a cascade of cellular dysregulation. [4] These antibodies actively influence cellular functions, notably by altering gene expression in circulating monocytes. [4] This suggests a receptor-mediated activation where aPL binding initiates intracellular signaling cascades within these immune cells, leading to a profound impact on downstream immune responses and contributing to the prothrombotic state characteristic of APS.
Further mechanistic insights into cellular signaling involve proteins like SESTD1, a phospholipid-binding protein identified as a regulator of the transient receptor potential channels TRPC4 and TRPC5. [1] While not directly detailed as an aPL target, the modulation of TRPC channel activity, which is crucial for calcium signaling and various cellular processes, could be indirectly affected by aPL-induced changes in phospholipid environments or cell surface receptor interactions. Such alterations in ion channel function could impact cellular activation, adhesion, and other physiological responses, thereby contributing to the cellular dysfunction observed in APS.
Genetic and Post-Translational Regulatory Networks
The genetic basis for the presence of aPL and the development of APS has been suggested, with genome-wide association studies (GWAS) identifying several suggestive novel loci that may confer susceptibility to antibody production. [1] These genetic factors likely contribute to the regulation of genes involved in immune responses and coagulation. Specifically, the protein β2-glycoprotein I (APOH), a key autoantigen in APS, can exhibit structural variations; the Val247Leu allelic variant has been associated with APS. [1] These genetic predispositions, alongside potential post-translational modifications, directly affect the structure and function of β2-glycoprotein I, influencing its interaction with aPL and its role in disease pathogenesis.
Beyond genetic polymorphisms, regulatory mechanisms encompass protein modification and shedding events crucial for immune modulation. The ER aminopeptidase ERAP1 exemplifies such regulation, as it is involved in trimming precursors for MHC class I peptides and is also required for the shedding of the interleukin-6 receptor. [3] While the direct involvement of ERAP1 in APS is not explicitly detailed, dysregulation in aminopeptidase activity could broadly affect antigen presentation to T cells or alter cytokine signaling, thereby contributing to the sustained immune activation and inflammation seen in autoimmune conditions like APS.
Autophagy, Apoptosis, and Cellular Homeostasis
The maintenance of cellular homeostasis, particularly through the intricate balance of autophagy and apoptosis, is a critical pathway that can be dysregulated in autoimmune diseases relevant to APS. The transmembrane protein TMEM166 plays a role in regulating both cell autophagy and apoptosis. [1] Impaired regulation of these processes can lead to the defective clearance of apoptotic cells, a known feature in systemic autoimmunity. [1] The accumulation of uncleared apoptotic debris can expose intracellular autoantigens, including phospholipids, which may initiate or perpetuate autoimmune responses and the generation of aPL.
Furthermore, mitochondrial dysfunction represents a significant metabolic pathway dysregulation with systemic implications. Abnormal regulation of mitochondrial function, often characterized by a reduced electron transport chain, leads to increased production of reactive oxygen species (ROS). [18] This oxidative stress not only impairs cellular energy metabolism by affecting the tricarboxylic acid cycle and ATP activity but also stimulates proinflammatory processes and mutagenesis. [18] These interconnected metabolic defects contribute to cellular damage and inflammation, exacerbating the overall pathology observed in APS.
Vascular Remodeling and Metabolic Crosstalk
The thrombotic events that define APS involve complex interactions within the vascular system, including processes of cellular remodeling. Platelet-derived growth factor (PDGF) signaling is a key pathway in this context, known to reorganize the actin cytoskeleton in cells, a process vital for cell migration, adhesion, and maintaining vascular integrity. [18] Dysregulated PDGF signaling, potentially initiated or exacerbated by aPL, could contribute to the prothrombotic environment by altering endothelial cell function and promoting an aberrant vascular response.
Moreover, there is evidence of significant crosstalk between these vascular mechanisms and broader metabolic pathways. Pathways related to PDGF signaling, PPAR signaling, and electron carrier activity (reflecting mitochondrial electron transport) have been identified as top-ranking pathways in conditions like metabolic syndrome. [18] Abnormal regulation of mitochondrial function, including reduced electron transport chain activity, can lead to insulin resistance and systemic inflammation. [18] While primarily studied in metabolic syndrome, these systemic metabolic dysregulations could contribute to vascular pathology and inflammation in APS, highlighting a complex systems-level integration where metabolic health influences disease progression and severity.
Epidemiological Context and Cohort Studies
Large-scale population-based cohort studies provide crucial insights into the prevalence and associations of antiphospholipid antibodies (aPL). The Gutenberg Health Study (GHS), a significant cohort of German descent, investigated approximately 5,000 individuals to determine the presence of various aPL, including IgG and IgM against cardiolipin, β2-glycoprotein 1 (anti-β2GPI), and IgG against domain 1 of β2-glycoprotein 1. [4] This study aimed to identify genetic factors linked to aPL presence and to clarify the impact of aPL on gene expression in circulating monocytes, with monocyte gene expression data collected from a subgroup of 1,279 individuals. [4] Such extensive cohorts are instrumental for establishing baseline epidemiological data and exploring the intricate interplay between genetic predispositions and the presence of these antibodies in the general population.
Genetic Epidemiology and Cross-Population Insights
Genome-Wide Association Studies (GWAS) have been employed to uncover the genetic underpinnings of antiphospholipid antibodies. One study conducted a GWAS to identify susceptibility loci for three main aPL: anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), and anti-β2GPI. [1] This research genotyped hundreds of individuals for each antibody type, utilizing Affymetrix 6.0 arrays, and identified several suggestive novel loci with P-values less than 1E-05, although these did not reach the conservative threshold for genome-wide significance. [1] While studies like these primarily focus on populations of European descent, the broader field of population genetics also investigates genetic variations across diverse ethnic and geographic groups, such as Japanese and Korean populations, to understand ancestry-specific genetic contributions to various traits. [19] This cross-population perspective is essential for determining the generalizability of genetic findings and identifying potential population-specific effects on antibody production.
Methodological Rigor in Population Genetic Studies
The robustness of population genetic studies relies on stringent methodologies to ensure accurate and reliable findings. Genotyping in these studies frequently employs platforms such as the Affymetrix Genome-Wide Human SNP Array 6.0 [4] or various Illumina BeadChips. [20] Critical quality control (QC) procedures are universally applied, including the exclusion of samples with low call rates, filtering out single nucleotide polymorphisms (SNPs) that deviate significantly from Hardy-Weinberg equilibrium, or have low minor allele frequencies. [21] Furthermore, to mitigate the confounding effects of population stratification due to varied ancestral backgrounds, researchers routinely perform principal component analysis (PCA) or multidimensional scaling (MDS) and incorporate these components as covariates in their association analyses. [1] These rigorous steps are fundamental for enhancing the representativeness of the sample and the generalizability of the genetic associations identified within specific populations.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs79154414 | LINC01812 - FBXL12P1 | antiphospholipid syndrome |
| rs2288493 | TSHR | antiphospholipid syndrome |
| rs145365907 | NGF-AS1 - ELOCP20 | antiphospholipid syndrome |
| rs1020096 | LINC02676 - LINC00709 | antiphospholipid syndrome |
| rs12570849 | FRMD4A | antiphospholipid syndrome |
| rs2788869 rs1225763 |
SYCP2L | antiphospholipid syndrome |
| rs1024843 | PTPRO | antiphospholipid syndrome |
| rs10886503 | GRK5 - RGS10 | antiphospholipid syndrome |
| rs1443267 | RN7SKP94 - MRPS23 | antiphospholipid syndrome |
| rs2395166 | TSBP1-AS1 - HLA-DRA | susceptibility to hepatitis B infection measurement OSCAR/TNFRSF14 protein level ratio in blood antiphospholipid syndrome hemoglobin measurement rheumatoid arthritis, chronic interstitial cystitis |
Frequently Asked Questions About Antiphospholipid Syndrome
These questions address the most important and specific aspects of antiphospholipid syndrome based on current genetic research.
1. My mom has APS. Will I get it too?
Not necessarily. While genetics play a role in APS susceptibility, it's not a simple one-gene condition. Many factors contribute, so having a family member with APS doesn't mean you'll automatically develop it.
2. Can a simple DNA test tell me my APS risk?
Not really, not yet. Scientists are still researching the specific genetic links to APS, and current studies haven't found strong, definitive genetic markers for predicting your risk. More research is needed.
3. Does my ethnic background change my APS risk?
Potentially, yes. Genetic risk factors can vary between different ancestral groups. Research on APS genetics is still expanding to include diverse populations to understand these differences better.
4. My sibling has APS, but I don't. Why the difference?
APS is complex, not just about one gene. Even with shared genetics, environmental factors and other unknown genetic influences can make a big difference in who develops the condition.
5. Can my lifestyle affect my genetic chances of getting APS?
It's very likely. Researchers believe that many environmental factors interact with your genes to influence APS development, but the exact connections are still being explored.
6. If I have lupus, does that raise my APS genetic risk?
Yes, it might. Antiphospholipid antibodies are often found in people with other autoimmune conditions like lupus, suggesting a shared genetic predisposition or immune pathways.
7. Will my genes tell me if I'll have APS blood clots or miscarriages?
Currently, no. While genetics play a part in developing APS, we don't yet have specific genetic markers that can predict which clinical problems, like clots or pregnancy issues, you might experience.
8. Why is APS more common in women? Is it genetic?
APS does affect more women, especially those of childbearing age. While this observation is clear, the specific genetic reasons for this gender difference are still not fully understood.
9. Could my past miscarriages be linked to genetic APS?
It's a possibility. Recurrent miscarriages are a known complication of APS, and genetics do influence susceptibility to the syndrome. It's something to discuss with your doctor.
10. Can I "turn off" my APS genetic risk somehow?
We don't fully understand how to "turn off" specific genetic risks for APS. Since the genetics are still complex and being researched, focusing on overall health and managing known risk factors is important.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Kamboh, M. I. "Genome-wide association study of antiphospholipid antibodies." Autoimmune Diseases, 2013.
[2] Burgner, D. "A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease." PLoS Genetics, 2009.
[3] Tsai, F. J. "Identification of novel susceptibility Loci for kawasaki disease in a Han chinese population by a genome-wide association study." PLoS One, 2011.
[4] Muller-Calleja, N. "Antiphospholipid antibodies in a large population-based cohort: genome-wide associations and effects on monocyte gene expression." Thrombosis and Haemostasis, 2016.
[5] Khor, C. C. "Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1." Nature Genetics, 2011.
[6] Gigante, A., M. L. Gasperini, R. Cianci, et al. “Antiphospholipid antibodies and renal involvement.” American Journal of Nephrology, vol. 30, no. 5, pp. 405–412, 2009.
[7] Mehrani, T., and M. Petri. "IgM anti-𝛽2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus." Journal of Rheumatology, vol. 38, no.
[8] Athanasiadis, G., et al. "A genome-wide association study of the Protein C anticoagulant pathway." PLoS One.
[9] Katz, D. H., et al. "Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease." Circulation.
[10] Acosta-Herrera, M., et al. "Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases." Annals of the Rheumatic Diseases.
[11] Gutierrez-Achury, J., et al. "Functional implications of disease-specific variants in loci jointly associated with coeliac disease and rheumatoid arthritis." Hum Mol Genet.
[12] Kiryluk, K., et al. "Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy." Nature Genetics.
[13] Miller, F. W., et al. "Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders." Arthritis & Rheumatism.
[14] Takenaka, K., et al. "Role of phospholipase C-L2, a novel phospholipase C-like protein that lacks lipase activity, in B-cell receptor signaling." Molecular and Cellular Biology, vol. 23, 2003, pp. 7329-38.
[15] Pietzner, M., et al. "Mapping the proteo-genomic convergence of human diseases." Science.
[16] Javierre, B. M., et al. "Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters."
[17] Sokolove, J., et al. "Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis." Arthritis & Rheumatism, vol. 65, 2013, pp. 1719-24.
[18] Shim, U., et al. "Pathway Analysis of Metabolic Syndrome Using a Genome-Wide Association Study of Korea Associated Resource (KARE) Cohorts." Genomics Inform, vol. 13, no. 4, 2015, pp. 136-143.
[19] Nakano, M. "Novel common variants and susceptible haplotype for exfoliation glaucoma specific to Asian population." Scientific Reports, 2014.
[20] Faraco, J., et al. "ImmunoChip study implicates antigen presentation to T cells in narcolepsy." PLoS Genet, vol. 9, no. 3, 2013, p. e1003270.
[21] Hayes, M. G. "Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations." Nature Communications, 2015.